Abcellera Biologics Inc ABCL

$12.50 +0.62 (5.22%)

Valuation

Market cap
3,642,539,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,987,700
Avg volume
4,371,296
Day's range
$11.68 – $12.74
Shares out
306,611,000
Stochastic %K
56%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

snowPOW Nov 10, 7:40 AM
$ABCL Fantastic ER, the road to 20B+
0 replies
Quadruple_Double Nov 10, 6:04 AM
$ABCL $15 would be nice. Then cruise to $20 by end of the year. 😆
0 replies
Merlintrader Nov 10, 6:02 AM
$ABCL AbCellera (ABCL): Q3 revenue $10.6M, liquidity over $890M Weekly catalysts newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
shoc24 Nov 10, 5:54 AM
$ABCL reported earnings after the close today. GAAP EPS beat estimates: -$0.13 vs. -$0.17 expected, according to Stock Meadow.
0 replies
Stocktradesmoon Nov 10, 3:02 AM
$ABCL “We have the proverbial goose in place, and now it is time for some golden eggs.” $ABCL CEO Carl Hansen | May 2026 They now have several in-house programs, including 635 in ph3. The number of programs will continue to grow, and they all aim to be first or best in class with a high TAM. Along with a growing portfolio of TCE collaborations. With ~$900M in liquidity. I’m excited to watch the coming years unfold. 🪿
0 replies
Buying_Low_Selling_High Nov 10, 2:52 AM
$ABCL For me this was the best part of the call. They expect 635 to demonstrate better results even when compared against Hormonal therapy. We are now talking about increasing the TAM by 2x - 3x times. 6 Billion TAM now becomes 15-20B. Absolutely incredible potential ahead.
1 replies
Stocktradesmoon Nov 10, 2:15 AM
$ABCL $HIMS $IAM $REGN $PFE $ABCL could be valued today at $15-20B given its accomplishments + potential. It would be a rich valuation and would take some time before it grew into such a mkt cap and then beyond, but it could definitely be supported in today’s market. Instead, it trades at $4B. $30+ stock!!
0 replies
beestMod516 Nov 10, 1:01 AM
$IBRX vs $ABCL vs $MRNA
0 replies